October 5, 2018
Omni Willliam Penn Hotel 530 William Penn Place Pittsburgh, Pennsylvania 15219
Both heart failure and pulmonary hypertension remain a major burden on society with a very high morbidity and mortality. Heart failure is the leading cause of cardiovascular death and the number one cause of hospitalization in the United States. Pulmonary hypertension often co-exists with heart failure and worsens morbidity and mortality. Heart failure is also a leading cause of cardiogenic shock which carries with a greater than 80% in hospital mortality. Several large clinical trials conducted over the past two decades have shown that pharmacologic interventions, surgery, and device- therapy can dramatically reduce the morbidity and mortality associated with both heart failure and pulmonary hypertension.
Based on evidence, new clinical practice guidelines have been developed for medical and surgical management of these patients. Despite these evidence-based guidelines, it has been shown that providers do not consistently follow recommendations in clinical practice. Unfortunately, this often results in patients being referred late in the disease for advanced therapies, leading to their unsuitability for such therapies.
Contact Information: Bernice Sulkowski Coordinator, Continuing Medical Education email@example.com